Koelis Announces New Compact 3D Probe to Improve Workflow and Reprocessing
September 25 2024 - 9:07AM
Koelis, SAS (“Koelis” or the “Company”, www.koelis.com), a global
leader and innovator in prostate care, announced today the release
of a new, compact 3D transducer for transperineal fusion biopsy and
treatment. Koelis is now compatible with both the market leading
high-level disinfection systems (Trophon® and Astra®VR).
As the policies and procedures for ultrasound
probe reprocessing continue to evolve, Koelis has reengineered our
popular transperineal side-fire 3D probe to allow compatibility
with the market leading auto re-processing systems in the USA. Its
new compact 3D transducer retains the same functionality and
ultrasound image quality. The redesign also allowed us to make a
significant improvement on the SteadyPro® adaptor that is used to
support the new compact probe during the procedure and offers
easier movement of the ultrasound probe when targeting regions of
interest in the prostate during an MRI guided fusion biopsy or
treatment.
Michael Daneshvar, MD Chief, Division of
Urologic Oncology at UC Irvine commented “Years ago we anticipated
the shift to transperineal MRI fusion biopsy and chose Koelis at
UCI for its accuracy and user-friendly software. As our patient
volume grew, we started to shift patients to our clinic and
implemented TP biopsy under local anesthesia, which the Koelis
Trinity platform is very much suitable for. We quickly realized
that a fusion biopsy with local anesthesia relies on an efficient
and accurate workflow that is tolerable for the patient, so we are
really happy Koelis found the solutions to improve our reprocessing
workflow with this new Trophon® compatible probe. As a result of
this redesign, my work as the urologist performing the biopsy is
also improved with the new stepper design which makes it easier to
perform targeted biopsies.”
Mr. Mark Rooney, Koelis VP & General Manager
in the USA, commented: “We are excited to bring this new probe to
market. Koelis has listened to our customers and this newly
re-engineered Koelis compact transperineal probe helps ensure we
remain the technology of choice for US customers looking to start a
new MRI Fusion program or upgrade from another technology.”
The Koelis Trinity® system enables urologists to
perform 3D targeted fusion biopsy in prostate cancer. Trinity
integrates 3D ultrasound imaging with proprietary MRI-US fusion
image guidance that features the Company’s unique prostate motion
tracking software (OBT Fusion®). The compact Koelis Trinity® system
does not require interfaces with either external ultrasound
equipment or external sensors and the versatility of the Trinity
platform is enabling Koelis to lead the ongoing paradigm shift in
prostate cancer care to more accurate biopsy diagnoses and more
choices for less invasive treatments.
About KOELIS
Headquartered in Grenoble, France, Koelis has
been a pioneer and leader of MRI-US fusion image guidance
technology since 2006. Featuring proprietary 3D ultrasound and
prostate motion tracking software (OBT Fusion®), the Koelis
Trinity® system facilitates more accurate biopsy diagnosis as well
as enabling “focal” prostate cancer treatment alternatives to
traditional “total” organ treatments such as surgical prostatectomy
and radiation. The Company’s commitment to minimally invasive
prostate cancer treatments includes a multi-center clinical
registry (“Violette”, NCT04582656) in Europe based on
Trinity-guided microwave ablation technology. Koelis has offices in
Grenoble (France), Princeton (NJ, USA), Saarbrücken (Germany) and
Singapore to serve more than 50 countries. Learn more about KOELIS
at www.koelis.com.
For KOELIS media inquiries, please contact:
Scott LeventonKoelis Inc. Phone: 800-579-9451Email:
Scott.leventon@koelis.com
A photo accompanying this announcement is
available
at https://www.globenewswire.com/NewsRoom/AttachmentNg/9b92be91-6175-4429-89f0-a597db89fb47